Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by State Street Corp

State Street Corp cut its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 8.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,113,590 shares of the company’s stock after selling 107,786 shares during the period. State Street Corp owned 2.75% of Keros Therapeutics worth $64,666,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in KROS. KBC Group NV increased its position in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new position in Keros Therapeutics in the third quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics during the second quarter worth about $128,000. Finally, LMR Partners LLP purchased a new stake in shares of Keros Therapeutics in the third quarter worth about $213,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Stock Down 4.8 %

Shares of NASDAQ KROS opened at $17.13 on Thursday. The stock’s 50 day moving average price is $56.64 and its two-hundred day moving average price is $52.06. Keros Therapeutics, Inc. has a 52-week low of $15.67 and a 52-week high of $73.00. The stock has a market capitalization of $693.88 million, a P/E ratio of -3.29 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company’s quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.33) earnings per share. On average, analysts anticipate that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on KROS. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Wells Fargo & Company upped their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Scotiabank decreased their price objective on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a research report on Friday, December 13th. Finally, TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $81.33.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.